Syntaxin
Abingdon
About Syntaxin
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Total funding: $71.4M
- Funding stage: M&A
- Last round: Series C (Nov 2010)
- Website: syntaxin.com
- Phone: +33 1 58 33 50 00
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/syntaxin-2632053 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.